No Prescription |
 |
 | ||
|
TEROL LA Detrol |
|
| ||
No Prescription » Prescription Drugs 16 » TEROL LA Detrol Tolterodine is used for: Treating overactive bladder with symptoms of urinary frequency urgency and leakage. Tolterodine reduces spasms of the bladder muscles. Tolterodine is used to treat overactive bladder with symptoms of urinary frequency urgency and incontinence. Buy TEROL LA Detrol and other Prescription Drugs 16 products online at Medstore. 3751
About TEROL LA Detrol: Product Type: Prescription Drugs 16 TEROL LA ( Detrol Detrol LA Generic Tolterodine ) TEROL LA (Detrol Detrol LA Generic Tolterodine) Detrol Detrol LA Generic Tolterodine 4mg Capsules 30 ( 3 x 10 ) Detrol Detrol LA Generic Tolterodine TEROL LA
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
